Vericel Revenue Rises 26% to $85.4 Million, Raises 2026 Guidance
Vericel reported Q3 2026 revenue of $85.4M, up 26% YoY, with net income of $14.2M. Adjusted EBITDA was $25.2M, or 30% of revenue. The company raised full-year revenue guidance to $344M-$346M. MACI and Burn Care revenue grew 21% and 52%, respectively. Vericel repurchased 220,744 shares for $8.8M.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide fresh data for valuation models and may trigger short‑covering.
Market read
First‑report earnings and guidance lift for a small‑cap biotech, offering a clear trading catalyst.
What to watch
Share repurchase size is modest relative to cash flow; future regulatory approvals remain uncertain.
Background
Vericel (VCEL) is a U.S. biotech focused on cell‑based therapies for cartilage repair and severe burns.
Ticker impact
Vericel reported Q3 2026 revenue up 26% and raised full-year revenue guidance to $344‑$346 million.
potential upside as the market prices in higher revenue expectations
The company beat prior quarter results and increased guidance, a clear catalyst for price appreciation.
Market effects
Higher MACI and burn‑care product sales may boost the regenerative‑medicine sector.
U.S. biotech investors may re‑weight exposure to small‑cap regenerative firms.
Limited to niche biotech space; no broad market impact.
Counterpoint
Guidance could be overly optimistic if BARDA procurement does not materialize as expected.
Key entities
- companyVericel Corp
Issuer of the earnings release.
- government_agencyBARDA
U.S. Biomedical Advanced Research and Development Authority, source of procurement revenue.
